Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies
Abstract Background Galcanezumab, a humanized monoclonal antibody that selectively binds to calcitonin gene-related peptide, has demonstrated a significant reduction in monthly migraine headache days in phase 2 and 3 trials. In these analyses, we aimed to evaluate the safety and tolerability of galc...
Guardat en:
| Autors principals: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMC
2020-01-01
|
| Col·lecció: | BMC Neurology |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1186/s12883-020-1609-7 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|